Uptravi for PAH to receive NHS England funding 9 January 2019 - Zenopa

Uptravi for PAH to receive NHS England funding 9 January 2019  Zenopa

Treatment for the rare and incurable disease pulmonary arterial hypertension, which affects approximately 3,000 people in the UK, has been available in all of ...



Comments

Post a Comment

Popular posts from this blog

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

Image
Overview Shortness of breath (dyspnea) is most commonly caused by heart or lung conditions. Other causes include anemia, anxiety, lack of exercise or living with obesity. What is dyspnea (shortness of breath)? Dyspnea (pronounced "DISP-nee-uh") is the word healthcare providers use for feeling short of breath. You might describe it as not being able to get enough air ("air hunger"), chest tightness or working harder to breathe. Shortness of breath is often a symptom of heart and lung problems. But it can also be a sign of other conditions like asthma, allergies or anxiety. Intense exercise or having a cold can also make you feel breathless. What are paroxysmal nocturnal dyspnea (PND) and sighing dyspnea? Paroxysmal nocturnal dyspnea (PND) is a feeling like you can't breathe an hour or two after falling asleep. Sighing dyspnea is when you sigh a lot after taking deep breaths in to try to relieve the feeling of dyspnea. What is the differ...
Read more

AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country - Nasdaq

AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country    Nasdaq AIT to receive up to $32.5 million in up-front and regulatory milestones. Additionally, AIT to receive a 15%-20% royalty on annual gross profit..
Read more

Clinical Management and Transplant Considerations in Pediatric Pulmonary Hypertension Due to Left Heart Disease: A Scientific Statement From the American Heart Association

Image
chronic thromboembolic disease :: Article Creator Anoikis, Form Of Natural Cell Death, May Help In Diagnosing CTEPH Anoikis, a form of programmed cell death, is involved in the development of chronic thromboembolic pulmonary hypertension (CTEPH), according to a genetic analysis study. Researchers identified two anoikis-related genes associated with CTEPH — PLAUR and HMOX1 — which may serve as diagnostic biomarkers or as treatment targets. Data also suggest that stannsoporfin, a drug that inhibits the protein encoded by HMOX1, may offer a way of treating CTEPH patients, the scientists, all in China, reported. The study, "Identification of Anoikis-related potential biomarkers and therapeutic drugs in chronic thromboembolic pulmonary hypertension via bioinformatics analysis and in vitro experiment," was published in Nature Scientific Reports. Activity levels of 2 genes higher in blood of people with CTEPH In CTEPH, a rare form of...
Read more